Hepatic Assist Devices: Will They Ever Be Successful?

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2009 Jan 27

PMID 19166661

Citations 3

Authors

Norman L Sussman

Brendan M McGuire

James H Kelly

Affiliations

Soon will be listed here.

Abstract

Hepatic assist remains elusive. Bioartificial livers (BALs), consisting of liver cells or tissue in a synthetic housing, have been promising but have not proven successful in clinical trials. Artificial livers that consist of sophisticated sorbents and membranes cannot support a failing liver but may shorten episodes of acute decompensation in patients with stable cirrhosis. These artificial livers are most likely to find a place as temporary support prior to transplantation. True liver support will require a BAL. This article proposes goals for making a clinically useful BAL, with attention to systems biology and potential sources of hepatocytes.

Citing Articles

Experimental bio-artificial liver: Importance of the architectural design on ammonia detoxification performance.

Pizarro M, Mamprin M, Daurelio L, Rodriguez J, Mediavilla M World J Hepatol. 2018; 10(10):719-730.

PMID: 30386465 PMC: 6206149. DOI: 10.4254/wjh.v10.i10.719.

Cell therapies for liver diseases.

Yu Y, Fisher J, Lillegard J, Rodysill B, Amiot B, Nyberg S Liver Transpl. 2011; 18(1):9-21.

PMID: 22140063 PMC: 3245367. DOI: 10.1002/lt.22467.

Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver.

Nedredal G, Amiot B, Nyberg P, Luebke-Wheeler J, Lillegard J, McKenzie T Biotechnol Bioeng. 2009; 104(5):995-1003.

PMID: 19557829 PMC: 2866646. DOI: 10.1002/bit.22450.

References

Demetriou A, Brown Jr R, Busuttil R, Fair J, McGuire B, Rosenthal P . Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004; 239(5):660-7. PMC: 1356274. DOI: 10.1097/01.sla.0000124298.74199.e5. View

Strain A, Neuberger J . A bioartificial liver--state of the art. Science. 2002; 295(5557):1005-9. DOI: 10.1126/science.1068660. View

Poyck P, Mareels G, Hoekstra R, van Wijk A, van der Hoeven T, van Gulik T . Enhanced oxygen availability improves liver-specific functions of the AMC bioartificial liver. Artif Organs. 2007; 32(2):116-26. DOI: 10.1111/j.1525-1594.2007.00500.x. View

Dixit V, Gitnick G . Artificial liver support: state of the art. Scand J Gastroenterol Suppl. 1996; 220:101-14. DOI: 10.3109/00365529609094760. View

Sussman N, Chong M, Koussayer T, He D, Shang T, Whisennand H . Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology. 1992; 16(1):60-5. DOI: 10.1002/hep.1840160112. View

Sussman N, Kelly J . Artificial liver: a forthcoming attraction. Hepatology. 1993; 17(6):1163-4. DOI: 10.1002/hep.1840170632. View

Sussman N, Kelly J . Improved liver function following treatment with an extracorporeal liver assist device. Artif Organs. 1993; 17(1):27-30. DOI: 10.1111/j.1525-1594.1993.tb00381.x. View

Mavri-Damelin D, Damelin L, Eaton S, Rees M, Selden C, Hodgson H . Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng. 2007; 99(3):644-51. DOI: 10.1002/bit.21599. View

Hassanein T, Tofteng F, Brown Jr R, McGuire B, Lynch P, Mehta R . Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007; 46(6):1853-62. DOI: 10.1002/hep.21930. View

10.

Olumide F, Eliashiv A, Kralios N, Norton L, Eiseman B . Hepatic support with hepatocyte suspensions in a permeable membrane dialyzer. Surgery. 1977; 82(5):599-606. View

11.

Stadlbauer V, Davies N, Sen S, Jalan R . Artificial liver support systems in the management of complications of cirrhosis. Semin Liver Dis. 2008; 28(1):96-109. DOI: 10.1055/s-2008-1040324. View

12.

Sussman N, Kelly J . Extracorporeal liver support: cell-based therapy for the failing liver. Am J Kidney Dis. 1997; 30(5 Suppl 4):S66-71. DOI: 10.1016/s0272-6386(97)90544-8. View

13.

Lee W, Squires Jr R, Nyberg S, Doo E, Hoofnagle J . Acute liver failure: Summary of a workshop. Hepatology. 2008; 47(4):1401-15. PMC: 3381946. DOI: 10.1002/hep.22177. View

14.

Chamuleau R, Poyck P, van de Kerkhove M . Bioartificial liver: its pros and cons. Ther Apher Dial. 2006; 10(2):168-74. DOI: 10.1111/j.1744-9987.2006.00359.x. View

15.

OGrady J, Gimson A, OBrien C, Pucknell A, Hughes R, Williams R . Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 1988; 94(5 Pt 1):1186-92. DOI: 10.1016/0016-5085(88)90011-x. View

16.

Hay D, Fletcher J, Payne C, Terrace J, Gallagher R, Snoeys J . Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A. 2008; 105(34):12301-6. PMC: 2518825. DOI: 10.1073/pnas.0806522105. View

17.

Lee W . Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatology. 2007; 46(4):966-70. DOI: 10.1002/hep.21926. View

18.

Kelly J, Darlington G . Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2. In Vitro Cell Dev Biol. 1989; 25(2):217-22. DOI: 10.1007/BF02626182. View

19.

Rozga J . Liver support technology--an update. Xenotransplantation. 2006; 13(5):380-9. DOI: 10.1111/j.1399-3089.2006.00323.x. View

20.

Cho C, Parashurama N, Park E, Suganuma K, Nahmias Y, Park J . Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: applications for the treatment of liver failure. FASEB J. 2007; 22(3):898-909. DOI: 10.1096/fj.06-7764com. View